X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
3.500
+0.170 (5.11%)
Mar 4, 2026, 4:00 PM EST - Market closed
X4 Pharmaceuticals Revenue
X4 Pharmaceuticals had revenue of $1.77M in the quarter ending September 30, 2025, with 215.18% growth. This brings the company's revenue in the last twelve months to $33.98M, up 2,925.73% year-over-year. In the year 2024, X4 Pharmaceuticals had annual revenue of $2.56M.
Revenue (ttm)
$33.98M
Revenue Growth
+2,925.73%
P/S Ratio
9.01
Revenue / Employee
$237,615
Employees
143
Market Cap
306.03M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.56M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 3.00M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 228.37M |
| Cellectis | 82.55M |
| XOMA Royalty | 47.11M |
| Fennec Pharmaceuticals | 38.79M |
| Opus Genetics | 14.63M |
| AC Immune | 5.48M |
| Adlai Nortye | -1.35M |
XFOR News
- 1 day ago - X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference - GlobeNewsWire
- 1 day ago - X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval - Seeking Alpha
- 2 days ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome - GlobeNewsWire
- 16 days ago - X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript - Seeking Alpha
- 4 weeks ago - X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 3 months ago - X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia - Seeking Alpha
- 4 months ago - X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference - GlobeNewsWire